Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
about
Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?Understanding the priorities for women diagnosed with lymphangioleiomyomatosis: a patient perspectiveUse of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestationsmTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management.Lymphangioleiomyomatosis: New Treatment Perspectives.Update in Interstitial Lung Disease 2014.Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract.Chronic sirolimus therapy for lymphangioleiomyomatosis.Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.Pseudoneutropenia in lymphangioleiomyomatosis (LAM) patients receiving sirolimus: evaluation in a 100 patient cohort.Recent advances in the management of lymphangioleiomyomatosis.
P2860
Q28075954-6D314AC4-0812-4695-B5F1-0A907AD5A221Q28596632-33D7B216-8A75-423E-96F6-0DB007348A29Q35971499-E5B416AE-1BB6-4E3E-B6A8-4DC8D4EA18FCQ37697798-99089F8F-5C46-4B42-B048-37EA96E376B4Q38372196-AEF3408C-DD94-4B80-AABD-FBF1505DDACFQ38414596-25CB3883-65A8-47ED-B2CB-3DAB73C09013Q38484497-D6203DD4-DD08-4243-8B6C-7F65799D458FQ38631673-75073786-D4B7-4F3C-8474-63E97B065ED9Q41970819-E5B5FCC8-2CC8-4DDD-95AD-9E73A6E26928Q48008829-675BA3F6-F750-492A-85E6-95BD543D6BB2Q48355779-53BF2C39-3D81-4777-836C-157EB7E31146Q49843469-41795BAF-EA81-461A-B21A-E3678DAD043BQ50092007-4C466570-E135-4C5B-A070-C119924C7613Q50630588-E702D67A-B077-4264-A10C-4497C7CF148AQ51779283-EE26E4BF-F341-43B0-ACB7-1AF6B7710D2DQ55322514-BC1C1CA5-6AA5-439D-B5C9-72819D0A5D3FQ55483958-2EA167E6-97D0-4BBE-BA7B-8CC8F0501A78
P2860
Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Sustained effects of sirolimus ...... s in lymphangioleiomyomatosis.
@en
type
label
Sustained effects of sirolimus ...... s in lymphangioleiomyomatosis.
@en
prefLabel
Sustained effects of sirolimus ...... s in lymphangioleiomyomatosis.
@en
P2093
P2860
P1476
Sustained effects of sirolimus ...... s in lymphangioleiomyomatosis.
@en
P2093
Amanda M Jones
Angelo M Taveira-DaSilva
Jianhua Yao
Mario Stylianou
Patricia Julien-Williams
P2860
P304
P356
10.1164/RCCM.201405-0918OC
P407
P577
2014-12-01T00:00:00Z